Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
Media Centre
>
Coverage
Overview
Video
Coverage
Coverage
29-Nov-2021
Kazia Therapeutics expands further in North America with Toronto glioblastoma study
15-Nov-2021
Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO
10-Nov-2021
Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled
7-Nov-2021
Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial
4-Nov-2021
Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy
28-Oct-2021
Kazia Therapeutics gets boost with ‘buy’ call from Maxim Group and valuation upgrade from Edison
14-Oct-2021
Kazia Therapeutics’ paxalisib program data garners increased target share price of A$2.83 from Edison
14-Sep-2021
Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference
2-Sep-2021
Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study
9-Dec-2020
Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial
Previous
1
2
3
4
5
6
7
8
Next
